EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS Net Assets
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS net assets. Based on the latest financial reports, EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC) has net assets worth TL57.41 Billion TRY (≈ $1.29 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (TL70.69 Billion ≈ $1.58 Billion USD) and total liabilities (TL13.28 Billion ≈ $297.36 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See EIS Eczacibasi Ilac Sinai ve Finansal Ya (ECILC) balance sheet quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | TL57.41 Billion |
| % of Total Assets | 81.22% |
| Annual Growth Rate | -25.82% |
| 5-Year Change | 749.78% |
| 10-Year Change | 1538.2% |
| Growth Volatility | 81.91 |
Net Assets of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (2000–2024)
Net assets of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS from 2000 to 2024. This chart illustrates how EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's net assets have evolved over time, based on quarterly financial data. Also explore net asset growth rate of EIS Eczacibasi Ilac Sinai ve Finansal Ya to track the company's year-over-year net asset growth rate.
Annual Net Assets for EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (2000–2024)
The table below shows the annual net assets of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS from 2000 to 2024. For live market cap and overall valuation, see EIS Eczacibasi Ilac Sinai ve Finansal Ya (ECILC) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | TL44.89 Billion ≈ $1.01 Billion |
-10.78% |
| 2023-12-31 | TL50.31 Billion ≈ $1.13 Billion |
+168.28% |
| 2022-12-31 | TL18.75 Billion ≈ $420.03 Million |
+153.57% |
| 2021-12-31 | TL7.40 Billion ≈ $165.65 Million |
+40.01% |
| 2020-12-31 | TL5.28 Billion ≈ $118.31 Million |
+23.50% |
| 2019-12-31 | TL4.28 Billion ≈ $95.80 Million |
+6.99% |
| 2018-12-31 | TL4.00 Billion ≈ $89.54 Million |
+14.86% |
| 2017-12-31 | TL3.48 Billion ≈ $77.96 Million |
+7.28% |
| 2016-12-31 | TL3.24 Billion ≈ $72.67 Million |
+18.41% |
| 2015-12-31 | TL2.74 Billion ≈ $61.37 Million |
-0.76% |
| 2014-12-31 | TL2.76 Billion ≈ $61.84 Million |
-5.45% |
| 2013-12-31 | TL2.92 Billion ≈ $65.40 Million |
+0.46% |
| 2012-12-31 | TL2.91 Billion ≈ $65.11 Million |
+11.07% |
| 2011-12-31 | TL2.62 Billion ≈ $58.62 Million |
+9.63% |
| 2010-12-31 | TL2.39 Billion ≈ $53.47 Million |
+9.00% |
| 2009-12-31 | TL2.19 Billion ≈ $49.06 Million |
+26.50% |
| 2008-12-31 | TL1.73 Billion ≈ $38.78 Million |
+3.25% |
| 2007-12-31 | TL1.68 Billion ≈ $37.56 Million |
+37.43% |
| 2006-12-31 | TL1.22 Billion ≈ $27.33 Million |
+29.03% |
| 2005-12-31 | TL945.68 Million ≈ $21.18 Million |
+75.26% |
| 2004-12-31 | TL539.60 Million ≈ $12.09 Million |
-100.00% |
| 2003-12-31 | TL436.00 Trillion ≈ $9.77 Trillion |
+335.64% |
| 2002-12-31 | TL100.08 Trillion ≈ $2.24 Trillion |
+106.42% |
| 2001-12-31 | TL48.48 Trillion ≈ $1.09 Trillion |
-16.85% |
| 2000-12-31 | TL58.31 Trillion ≈ $1.31 Trillion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 99.7% over the analyzed period, potentially due to dividend distributions or operating losses.
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS Net Assets Breakdown (December 2024)
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | TL26.43 Billion | 58.89% |
| Other Components | TL18.45 Billion | 41.11% |
| Total Equity | TL44.88 Billion | 100.00% |
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS Competitors by Market Cap
The table below lists competitors of EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Oneness Biotech Co Ltd
TWO:4743
|
$710.02 Million |
|
Riskified Ltd
NYSE:RSKD
|
$710.10 Million |
|
XOMA Royalty Corporation
NASDAQ:XOMA
|
$710.16 Million |
|
Restaurant Brands Asia Limited
NSE:RBA
|
$710.39 Million |
|
Chimera Investment Corporation
NYSE:CIM
|
$709.88 Million |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
$709.77 Million |
|
Keystone Electrical (Zhejiang) Co. Ltd. A
SHE:301448
|
$709.75 Million |
|
NICE Information Service Co. Ltd
KQ:030190
|
$709.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 50,307,880,000 to 44,884,087,000, a change of -5,423,793,000 (-10.8%).
- Net income of 1,023,611,000 contributed positively to equity growth.
- Dividend payments of 935,975,000 reduced retained earnings.
- Other factors decreased equity by 5,511,429,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | TL1.02 Billion | +2.28% |
| Dividends Paid | TL935.98 Million | -2.09% |
| Other Changes | TL-5.51 Billion | -12.28% |
| Total Change | TL- | -10.78% |
Book Value vs Market Value Analysis
This analysis compares EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.71x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 9.11x to 0.71x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | TL5.08 | TL46.26 | x |
| 2018-12-31 | TL5.83 | TL46.26 | x |
| 2019-12-31 | TL6.24 | TL46.26 | x |
| 2020-12-31 | TL7.71 | TL46.26 | x |
| 2021-12-31 | TL10.79 | TL46.26 | x |
| 2022-12-31 | TL27.36 | TL46.26 | x |
| 2023-12-31 | TL73.41 | TL46.26 | x |
| 2024-12-31 | TL65.50 | TL46.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.68%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.25x
- Recent ROE (2.28%) is below the historical average (6.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 7.00% | 3.87% | 0.83x | 2.17x | TL-1.75 Trillion |
| 2005 | 3.95% | 4.34% | 0.65x | 1.40x | TL-56.29 Million |
| 2006 | 3.02% | 3.66% | 0.57x | 1.44x | TL-83.84 Million |
| 2007 | 27.21% | 50.78% | 0.43x | 1.26x | TL285.56 Million |
| 2008 | 4.19% | 8.93% | 0.40x | 1.18x | TL-99.65 Million |
| 2009 | 13.37% | 33.18% | 0.35x | 1.15x | TL73.13 Million |
| 2010 | 2.55% | 6.61% | 0.34x | 1.12x | TL-176.47 Million |
| 2011 | 3.40% | 9.09% | 0.32x | 1.17x | TL-171.60 Million |
| 2012 | 1.14% | 3.01% | 0.31x | 1.22x | TL-253.28 Million |
| 2013 | 2.13% | 5.45% | 0.33x | 1.19x | TL-226.71 Million |
| 2014 | -1.58% | -4.14% | 0.32x | 1.19x | TL-317.68 Million |
| 2015 | 2.47% | 5.78% | 0.35x | 1.23x | TL-205.97 Million |
| 2016 | 5.68% | 13.08% | 0.35x | 1.23x | TL-140.27 Million |
| 2017 | 4.20% | 24.43% | 0.16x | 1.10x | TL-201.96 Million |
| 2018 | 6.01% | 34.69% | 0.16x | 1.11x | TL-159.66 Million |
| 2019 | 3.80% | 18.55% | 0.18x | 1.13x | TL-264.99 Million |
| 2020 | 6.10% | 35.43% | 0.15x | 1.13x | TL-206.14 Million |
| 2021 | 10.21% | 68.42% | 0.13x | 1.12x | TL15.49 Million |
| 2022 | 22.28% | 228.22% | 0.08x | 1.24x | TL2.30 Billion |
| 2023 | 7.86% | 42.28% | 0.15x | 1.25x | TL-1.08 Billion |
| 2024 | 2.28% | 11.68% | 0.16x | 1.25x | TL-3.46 Billion |
Industry Comparison
This section compares EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,299,278,352
- Average return on equity (ROE) among peers: 29.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC) | TL57.41 Billion | 7.00% | 0.23x | $710.00 Million |
| Deva Holding AS (DEVA) | $1.03 Billion | 27.75% | 1.06x | $315.83 Million |
| Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) | $2.80 Billion | 38.53% | 0.31x | $372.92 Million |
| Turk Ilac ve Serum Sanayi AS (TRILC) | $62.47 Million | 23.04% | 2.04x | $16.49 Million |
About EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S., together with subsidiaries, engages in health and real estate development businesses in Turkey and internationally. The Health segment is involved in the production, marketing, and sale of medicines related to human health and veterinary medicines. The Real Estate Development segment develops real estate properties; engages… Read more